Semaglutide will lose patent protection in India on March 21, 2026[3]. This drug is used to treat both diabetes and obesity, including the oral form[1]. India is among the large countries where the patent will expire in 2026, along with Canada, China, Brazil and Turkey, which account for 40% of the world's population and an estimated 33% of the adult population with obesity[1]. In India, more than 10 companies have already submitted applications to conduct phase III studies for semaglutide, of which 7 are focusing on the oral formulation[1]. The long court battle ended with the decision of the Dielsky High Court on December 2, which allowed Dr. Reddy's Laboratories to manufacture and export a generic version of semaglutide to countries without patent protection[2]. The company has pledged not to sell the product in the Indian market before the patent expires[2]. Lilly's Mounjaro (March 2025) and Novo's Wegovy (June 2025) recently launched in India, opening the door for competition shortly before patent expiration[1].